Replies to post #2189 on Idera Pharmaceuticals Inc (IDRA)

[binchey]

clearly great data

1 - DLBCL trial will show favorable results too (same type or targets)

2 -Higher doses increase worked better, this is a big plus

3 - 8400 is very well tolerated, another higher dosed trial in near future might provide even a slum drunk kind of results :)

[stocking4ms]

Thank you for posting. Good to know:
"Idera will host a conference call and live webcast on Monday, December 7 at 9:00 A.M. EST to review the data being presented at ASH along with discussion of next steps for the IMO-8400 development program in B-cell Lymphomas."